Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 9, Number 6, June 2017, pages 499-507

Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes

Figures

Figure 1.
Figure 1. Study flow chart.
Figure 2.
Figure 2. The change of HbA1c in Emirati patients. There is a significant reduction in HbA1c from baseline to 6 months and 1 year. However, the difference was not significant between 6 months and 1 year.
Figure 3.
Figure 3. The change of weight over time. There is significant reduction in weight from baseline to 6 months.

Table

Table 1. Baseline Characteristics
 
VariablesNo%
Age
  ≥ 65 years6721.8%
  < 6524078.2%
Mean ± SD54.4 ± 11.6
Weight85.3 ± 1685 - 143
Gender
  Male11336.8%
  Female19463.2%
Medications
  Long acting11437.1%
  Bolus8226.7%
  Metformin28091.2%
  DDP416252.8%
  GLP12440.4%
  SU14346.6%
  TZD278.8%
  Statins28091.2%
  Others3511.4%
Comorbidities
  HTN23275.6%
  Dyslipidemia22272.3%
  Hypothyroidism247.8%
  IHD3210.4%
  Others6220.2%
DM duration (years)14.03 ± 6.63 months – 37 years
SBP136 ± 1690 - 219
DBP74.2 ± 1940 - 178
FBG169 ± 5945 - 395
HbA1C8.7 ± 1.65 - 17
TC164.8 ± 4276 - 357
TG140.6 ± 8935 - 800
HDL48.9 ± 1318 - 134
LDL91.6 ± 3126 - 244
FBS171 ± 7345 - 395
Creatinine0.72 ± 0.220 - 1.6